Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Berlin
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

ImmuPharma PLC

+ Add to Watchlist

25I:GR

0.609 EUR 0.002 0.33%

As of 11:28:23 ET on 03/06/2015.

Snapshot for ImmuPharma PLC (25I)

Open: 0.608 Day's Range: 0.608 - 0.621 Volume: 0
Previous Close: 0.607 52wk Range: 0.470 - 0.802 1-Yr Rtn: -6.88%

Stock Chart for 25I

No chart data available.
  • 25I:GR 0.609
  • 1M
  • 1Y
0.607
Interactive 25I Chart

Previous Close

No chart data available.
Interactive Chart
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for 25I

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. DAX -
Earnings Per Share (GBP) (ttm) -
Est. EPS (GBP) (12/2014) -0.0510
Est. PEG Ratio -
Market Cap (M EUR) 53.97
Shares Outstanding (M) 88.62
30 Day Average Volume 67
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/21/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for 25I

  • Revenue
  • Net Income (M/GBP)
  • Profit Margin (%)

Company Profile & Key Executives for 25I

Immupharma PLC is a pharmaceutical company. The Company researches treatments for lupus, cancer, post-operative pain, and highly resistant hospital-acquired infections.

Dimitri F DimitriouChief Executive OfficerRobert ZimmerPresident/Chief Scientific Ofcr
Tracy WeimarVP:Operations & Finance/SecyLisa BaderoonHead:Investor Relations
More Company Profile & Key Executives for 25I

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil